Moderna (MRNA) stock contnues to tumble as J.P. Morgan and Jefferies downgrade the biotech following updates at the company's ...

Moderna's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

By investing heavily on EV R&D, India can further localise production to create more jobs, tap export markets to gain global ...

Moderna MRNA announced a strategic overhaul and new financial guidance at its R&D day on Sept. 12, and we’ve lowered our fair value estimate to $141 per share from $227. We’ve repeatedly ...

Focuses on ten product approvals through 2027 Expects to submit next-generation COVID vaccine for approval in 2024 Expects to submit flu/COVID combination vaccine for approval in 2024 Announces ...

Moderna Inc.’s shares (NASDAQ:MRNA) sank 19% to a $64.11 low in early trading Sept. 12 as investors learned during the annual ...

Moderna announced a strategic overhaul and new financial guidance at its R&D day on Sept. 12, and we’ve lowered our fair value estimate to $141 per share from $227. We’ve repeatedly pointed to ...

Drug maker Moderna, Inc. (MRNA), at its annual R&D Day event on Thursday, presented its outlook for fiscal 2025 and beyond, as well ...

Following an over 12% decline in the previous session in reaction to updates at the company’s R&D Day event, Moderna (NASDAQ:MRNA) shares continued to tumble in the pre-market on Friday as J.P ...

today announced program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline at its annual R&D Day event. The updates include data readouts in the Company ...